Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide.
Chanju LeeHyunju JeongYounghyeon BaeKyungmoon ShinSinwoo KangHwikyung KimJayoung OhHyunsu BaePublished in: Journal for immunotherapy of cancer (2019)
Taken together, our study demonstrated that MEL-dKLA could be used to target M2-like TAMs as a promising cancer therapeutic agent.